Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. No abstract available.

PMID:
31043386
2.

With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC.

Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. No abstract available.

PMID:
31003998
3.

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC.

Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12.

4.

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.

Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, Tai YT, Raines SE, Kuhstoss SA, Munshi NC, Kronenberg HM, Raje NS.

J Bone Miner Res. 2016 Jun;31(6):1225-34. doi: 10.1002/jbmr.2789. Epub 2016 Feb 19.

5.

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.

Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC.

PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015.

6.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

PMID:
25709080
7.

Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MAS, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL.

Cell Rep. 2015 Feb 10;10(5):755-770. doi: 10.1016/j.celrep.2015.01.017. Epub 2015 Feb 5.

8.

Role of decorin in multiple myeloma (MM) bone marrow microenvironment.

Nemani N, Santo L, Eda H, Cirstea D, Mishima Y, Patel C, O'Donnell E, Yee A, Raje N.

J Bone Miner Res. 2015 Mar;30(3):465-70. doi: 10.1002/jbmr.2371.

9.

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.

Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC.

Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. No abstract available.

10.

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther. 2014 Nov;13(11):2489-500. doi: 10.1158/1535-7163.MCT-14-0147. Epub 2014 Aug 29.

11.

CSNK1α1 mediates malignant plasma cell survival.

Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC.

Leukemia. 2015 Feb;29(2):474-82. doi: 10.1038/leu.2014.202. Epub 2014 Jun 25.

12.

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC.

Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16.

13.

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS.

Br J Haematol. 2014 Aug;166(3):401-9. doi: 10.1111/bjh.12909. Epub 2014 Apr 25.

PMID:
24761838
14.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
15.

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.

Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5.

16.

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N.

Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28.

17.

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.

Scullen T, Santo L, Vallet S, Fulciniti M, Eda H, Cirstea D, Patel K, Nemani N, Yee A, Mahindra A, Raje N.

Leukemia. 2013 Aug;27(8):1715-21. doi: 10.1038/leu.2013.50. Epub 2013 Feb 18.

PMID:
23417027
18.

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.

Bone. 2013 Apr;53(2):487-96. doi: 10.1016/j.bone.2013.01.012. Epub 2013 Jan 17.

19.

Estimating the prevalence of systemic sclerosis in the Lorraine region, France, by the capture-recapture method.

El Adssi H, Cirstea D, Virion JM, Guillemin F, de Korwin JD.

Semin Arthritis Rheum. 2013 Apr;42(5):530-8. doi: 10.1016/j.semarthrit.2012.10.001. Epub 2013 Jan 2.

PMID:
23290691
20.

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2012 Sep 1;18(17):4669-81. doi: 10.1158/1078-0432.CCR-12-0779. Epub 2012 Jul 17. Erratum in: Clin Cancer Res. 2019 May 1;25(9):2938.

Supplemental Content

Loading ...
Support Center